ACTRN12617001643369尚未招募1 期
Inhaled rifampicin safety and dose finding proof of concept study in healthy volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Provision of signed and dated informed consent form.
- •2. In good general health as evidenced by medical history, no current prescription medication usage, normal FEV1 (forced expiratory volume in 1 second, ), FVC (forced vital capacity) values, normal baseline liver function test values.
- •3. Ability to take oral and inhaled medication
排除标准
- •1. Current use of prescription medications or use in the past one month
- •2. Pregnancy or lactation.
- •3. History of asthma, or past respiratory condition and previous known exposure to TB.
- •4. Abnormalities on pulmonary function tests on screening and abnormalities in baseline liver function tests with ALT, ALP, BILI values > 3x ULN.
研究者
相似试验
招募中
1 期
Rifampicin at High Dose for Complex Tuberculosis, RIAlta studyPulmonary and extrapulmonary tuberculosisEUCTR2020-003146-36-NLVall d'Hebron Research Institute (VHIR)134
尚未招募
2 期
Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis10028440TuberculosisNL-OMON52031Vall dHebron University Hospital40
进行中（未招募）
不适用
Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphineEUCTR2012-002871-32-FITurku University hospital
Unknown
2 期
Rifampicin at High Dose for Difficult-to-Treat TuberculosisTuberculosisNCT04768231Hospital Universitari Vall d'Hebron Research Institute130
Unknown
不适用
Efficacy and safety of SPILs 1301 tablets, 200 mg in subjects with travelers diarrhea : A Randomized, Double blind, Parallel group, Active and Placebo Controlled, Clinical Endpoint Bio equivalence StudyCTRI/2017/03/007996Sun Pharmaceutical Industries Limited1